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ABSTRACT 
Purpose: Maintenance demonstrated to improve survival in newly diagnosed multiple myeloma 
(NDMM) patients and the achievement of complete response (CR) is a strong predictor of survival. 
Nevertheless, the role of maintenance according to response after induction/consolidation has not 
been investigated so far. To evaluate the impact of maintenance according to response, we pooled 
together and retrospectively analyzed data from 955 NDMM patients enrolled in two trials 
(GIMEMA-MM-03-05 and RV-MM-PI-209).  
Methods: Primary endpoints were progression-free survival (PFS)1, PFS2 and overall survival 
(OS) of CR patients randomized to maintenance and no maintenance. Secondary endpoints were 
PFS1, PFS2 and OS in very good partial response/partial response (VGPR/PR) patients. 
Results: Overall, 213 patients obtained CR after induction/consolidation; 118 received maintenance 
and 95 no maintenance. In patients achieving CR, maintenance significantly improved PFS1 (HR 
0.50, P<0.001), PFS2 (HR 0.58, P 0.02) and OS (HR 0.51, P 0.02) compared with no maintenance; 
the advantage was maintained across all the analyzed subgroups according to age, International 
Staging System (ISS) stage, cytogenetic profile and treatment. Similar features were seen in 
VGPR/PR patients. 
Conclusion: Maintenance prolonged survival in CR and in VGPR/PR patients. The benefit in CR 
patients suggests the importance of continuing treatment in patients with chemo-sensitive disease. 
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INTRODUCTION 
 
Multiple myeloma (MM) is an incurable plasma cell neoplasm that accounts for approximately 13% 
of hematologic cancers.(Altekruse et al. 2010) The standard of care for MM patients ineligible for 
autologous stem cell transplantation (ASCT) is the combination of melphalan-prednisone (MP) plus 
bortezomib (VMP) or thalidomide (MPT) or the association of lenalidomide and low-dose 
dexamethasone (Rd) (San Miguel et al. 2008; Mateos et al. 2010; Fayers et al. 2011; Benboubker et 
al. 2014). A progression-free survival (PFS) advantage with bortezomib in combination with Rd in 
comparison with Rd alone in patients who are not candidates to ASCT has recently been 
demonstrated (Durie et al. 2017).  
In patients eligible for ASCT, the standard approach consists of a novel agent based induction 
regimen (proteasome inhibitor and/or immunomodulatory drug) followed by high-dose melphalan 
and ASCT (MEL200-ASCT) (Moreau et al. 2015). 
Recent data clarified the role of maintenance therapy (Palumbo and Anderson 2011; Palumbo et al. 
2015). In patients ineligible for ASCT, continuous therapy with lenalidomide and dexamethasone 
improved PFS and overall survival (OS) as compared with MPT (Benboubker et al. 2014). A 
consistent survival advantage was also observed in patients treated with bortezomib-thalidomide 
(VT) maintenance (Palumbo et al. 2010, 2014a; Mateos et al. 2012). In patients eligible for ASCT, 
four different trials demonstrated the PFS advantage of lenalidomide maintenance (Attal et al. 2012; 
McCarthy et al. 2012; Palumbo et al. 2014b; Jackson et al. 2016a), while a recent meta-analysis has 
shown also a significant OS benefit (Attal et al. 2016). 
The association between depth of response and survival had been highlighted in many studies (van 
de Velde et al. 2007). So far only one randomized trial (Myeloma XI) investigated the role of a 
response-adapted approach. Preliminary results showed a response upgrade in around 40% of 
patients and a significant PFS improvement in patients achieving a suboptimal response after IMIDs 
who received sequential treatment with bortezomib-cyclophosphamide-dexamethasone (VCD). On 
the other hand, patients who reached very good partial response/complete response (VGPR/CR) did 
not receive any further induction, assuming that the achievement of high quality response may not 
need intensification (Jackson et al. 2016b). No trial has so far prospectively evaluated the effect of 
intensified treatment or prolonged treatment in patients achieving good quality responses. 
We pooled together data from two phase III trials comparing maintenance vs no maintenance. The 
aim of our analysis was to evaluate the impact of maintenance according to response achieved after 
induction/consolidation therapy. As primary objective, we evaluated the effect of maintenance 
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treatment in patients achieving high-quality response to induction/consolidation, defined as CR; as 
secondary objective, we analyzed the impact of maintenance in patients with suboptimal response 
(VGPR/PR) after induction/consolidation therapy. 
   
 
MATERIAL AND METHODS 
 
Patients and treatment 
We selected two phase III trials (GIMEMA-MM-03-05 and RV-MM-PI-209) coordinated by the 
same principal investigator. In both trials, newly diagnosed MM patients received maintenance or 
no maintenance after induction/consolidation. Details and results of the two studies were previously 
published (Palumbo et al. 2010, 2014b). Additional material and methods are reported in the 
Supplementary Appendix. 
 
Clinical endpoints 
The primary endpoints of the analysis were PFS1, PFS2 and OS in patients eligible to maintenance 
or no maintenance who achieved CR after induction/consolidation. Secondary endpoints were 
PFS1, PFS2 and OS in patients eligible to maintenance or no maintenance who achieved a 
VGPR/PR after induction/consolidation (Durie et al. 2006; European Medicines Agency 2012). 
PFS1, PFS2 and OS are defined in the supplementary material. 
 
Statistical analysis 
We performed a retrospective, non-preplanned analysis. Data from the two trials were pooled 
together and analysed. As patients were randomized at study entry but started maintenance after a 
median of 10 months from randomization (that corresponds to the median time of 
induction/consolidation) a landmark analysis with a landmark point at 10 months from start of 
therapy was performed. We included patients alive and progression free after 10 months from start 
of treatment, and who had achieved at least a partial response (PR) (Durie et al. 2006) after  
induction/consolidation. Patients were stratified according to response achieved (CR vs VGPR/PR).  
Time-to-event data were analyzed using the Kaplan–Meier method; treatment groups were 
compared with the log-rank test. The Cox proportional hazards models were used to estimate 
adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the main comparisons; 
Grambsch and Therneau test was used for testing the proportional hazard assumption.  
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To identify if the benefit of maintenance vs no maintenance varies in specific subsets of patients, 
subgroup analyses using interaction terms between treatment and each of the covariate included in 
the Cox model were performed. Patients were categorized according to age (<65, 66-75,>75), ISS 
Stage (I, II, III, missing data), cytogenetic risk (high [presence of at least one of the following: 
translocation (4;14), translocation (14;16), deletion 17], standard [absence of t(4;14), t(14;16) and 
deletion 17]) and trial (GIMEMA MM0305, RV-MM-PI-209; patients enrolled in the RV-MM-PI-
209 were also analyzed according to the specific pre-maintenance therapy received [MPR vs 
MEL200]).  
All HRs were estimated with their 95% CI and two sided p-values. Differences between categorical 
variables were examined by Fisher's exact test. Data were analyzed as of December, 2016 using R 
(Version 3.1.1).  
 
 
RESULTS 
 
Patients 
Data from 955 patients enrolled in the 2 trials were pooled together; 550 patients were eligible for 
maintenance. A total of 213 patients achieved a CR after induction/consolidation, 118 of them were 
randomized to maintenance and 95 to no maintenance. Three-hundred and sixteen patients achieved 
a VGPR/PR after induction/consolidation, 151 of them received maintenance treatment and 165 did 
not (Figure S1). Of 269 patients receiving maintenance, 120 discontinued within two years of 
therapy. The main reasons for discontinuation were PD (66%), toxicity (18%) and patients’ or 
medical decision (16%). Of note, rate of discontinuation of maintenance was higher in patients 
older than 75 years vs younger (68% vs 42%; P= 0.037). 
Patient demographics and disease characteristics in CR and VGPR/PR patients randomized to 
maintenance and no maintenance were well balanced (Table S1). High-risk patients (ISS stage III 
and high-risk cytogenetic profile) were equally distributed in the maintenance and no maintenance 
groups.  
 
CR population 
The median follow-up from landmark point was 56 months. The median PFS1 was 47 months for 
the maintenance group vs 28 months for the no maintenance group (HR 0.50, 95% CI 0.35-0.71, 
P<0.001) (Figure 1 Panel A). The PFS1 benefit associated with maintenance therapy was consistent 
in the different subgroups, although it was more pronounced in patients ≤65 years (HR 0.26) as 
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compared with those aged 66-75 years (HR 0.65) and >75 years (HR 0.89) (P=0.04 for interaction). 
In accordance, a more pronounced advantage in the RV-MM-PI-209 trial where only patients <65 
years were enrolled was noticed. No other differences were detected between the different analyzed 
subgroups (Figure 1 Panel B). 
The median PFS2 was not reached in the maintenance group and was 57 months in the no 
maintenance group (HR 0.58, 95% CI 0.37-0.91, P=0.02), suggesting a long-term survival benefit 
associated with maintenance treatment (Figure 2 Panel A). The PFS2 benefit with maintenance was 
consistent in all the different analyzed subgroups (Figure 2 Panel B). 
The 5-year OS was 82% vs 66% (median not reached in both groups), respectively in patients who 
received maintenance compared with those who did not (HR 0.51, 95% CI 0.29-0.91, P= 0.02), 
(Figure 3 Panel A). The OS advantage was confirmed among all analyzed subgroups, but it was less 
evident in patients with ISS stage I (HR 0.97) (Figure 3 Panel B). This analysis is however limited 
by the low number of events so far in this good prognosis group. 
 
VGPR/PR population 
The median follow-up from landmark point was 44 months. Of 151, 11 patients increased their best 
response during maintenance treatment. The median PFS1 was 28 months in the maintenance group 
vs 18 months in the no maintenance group (HR 0.55, 95% CI 0.42-0.72, P<0.001) (Figure S2 Panel 
A). Similarly to CR patients, the PFS1 benefit associated with maintenance therapy was consistent 
in all the analyzed subgroups, and it was more evident in patients ≤ 65 years (HR 0.5) and aged 66-
75 (HR 0.54) as compared with those aged >75 years (HR 0.86) (Figure S2 Panel B). 
The median PFS2 was 53 months vs 41 months in patients randomized to maintenance vs no 
maintenance (HR 0.64, 95% CI 0.46-0.89, P=0.01) (Figure S3 Panel A). No difference was 
observed in the subgroups analysis but the advantage was less evident again in patients aged > 75 
years (HR 0.78) (Figure S3 Panel B). 
The median OS was not reached in the two groups, and the 5-year OS was 63% vs 57% (HR 0.75, 
95% CI 0.50-1.12, P=0.16) (Figure S4 Panel A). The advantage was again more evident in patients 
aged < 65 years (HR 0.56) in comparison with those aged 66-75 years (HR 0.87) or >75 years (HR 
0.85) (Figure S4 Panel B).  
 
Interestingly, the highest survival rates (in terms of PFS1, PFS2 and OS) were noticed in CR 
patients receiving maintenance; survival of patients achieving a CR who did not receive 
maintenance was similar to the one of VGPR/PR patients treated with maintenance (Figure 4, Panel 
A, B, C). 
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DISCUSSION 
Previous reports demonstrated that maintenance treatment was associated not only with a PFS, but 
in some studies also with an OS advantage (Fayers et al. 2011; Attal et al. 2012, 2016; McCarthy et 
al. 2012; Palumbo et al. 2014a, b, 2015; Benboubker et al. 2014; Jackson et al. 2016a), and 
nowadays a growing number of clinical studies are including maintenance as part of the therapeutic 
approach. The impact on survival of achieving a CR in comparison with VGPR/PR is well known 
(van de Velde et al. 2007) and the value of prolonging treatment in patients with suboptimal 
response (VGPR/PR) is commonly recognized and accepted. Nevertheless, whether therapy should 
be continued in patients achieving CR remains an open issue. To the best of our knowledge, this 
pooled analysis is the first study to investigate the effect of a maintenance therapy in MM patients 
according to the response achieved after induction/consolidation.  
Prolonged treatment in patients with suboptimal response to therapy improved PFS1, PFS2 and OS, 
as expected (Figures S2, S3, S4). Of note, maintenance therapy significantly improved PFS1 (5-
year PFS1: 42 % vs 25%, HR 0.50, P<0.001), PFS2 (5-year PFS2: 62% vs 45%, HR 0.58, P=0.02) 
and OS (5-year OS: 82% vs 66%, HR 0.51, P=0.02) also in patients who achieved a CR after 
induction/consolidation (Figures 1, 2, 3). Within both response categories (CR and VGPR/PR 
populations), this benefit could depend on the ability of maintaining the best response achieved 
rather than on increasing response during maintenance therapy. In fact, only around 7% of 
VGPR/PR patients increased their response during maintenance. Unfortunately, no data on MRD 
evaluation were available, to evaluate if maintenance was able to improve the depth of response 
also in a proportion of CR patients. However, Jackson et al. recently showed that also MRD 
negative patients had a PFS benefit with maintenance therapy.(Jackson et al. 2016a) Both these 
findings suggest that prolonged treatment, in patients with chemo-sensitive disease and high-quality 
responses, is an effective strategy to at least maintain (if not to increase) the depth of response 
obtained during first line therapy and consequently to improve survival. 
In our analyses, the highest survival was observed in CR patients receiving maintenance; survival of 
patients achieving a CR who did not receive maintenance was similar to the one of VGPR/PR 
patients treated with maintenance (Figure 4), as if CR patients not receiving continuous therapy are 
likely to lose their potential advantage compared with patients obtaining a suboptimal response. 
Again, similar features were reported by Jackson et. al in MRD negative patients not receiving 
maintenance, who showed an outcome similar to MRD patients who received lenalidomide 
maintenance (Jackson et al. 2016a). 
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The subgroup analysis showed that the survival advantage for maintenance was retained in all the 
evaluated subsets of patients. In particular, the benefit derived from maintenance therapy was 
confirmed in both young and elderly patients; however, the reduction in the risk of 
progression/death was stronger in patients aged ≤65 years and 66-75 years if compared with 
patients >75 years (P of interaction = 0.04). Treatment discontinuation rate is commonly higher 
among elderly patients because of their intrinsic characteristics of frailty. Consequently the older 
population has the lowest benefit. In fact, in our study, the rate of discontinuation within 2 years 
was significantly higher in patients aged > 75 years, even though the analysis was limited by the 
low number of patients in this subgroup. A major limitation of this subgroup analysis is that most of 
patients <65 years were enrolled in the RV-MM-209 trial, while patients older than 65 were 
enrolled in the GIMEMA MM0305 trial. The two trials included two different treatment strategies: 
maintenance with VT was administered for up to 24 months in the GIMEMA-MM-03-05; 
lenalidomide maintenance was administered until progression in the RV-MM-PI-209 (median 
duration was 23 months). We did see a different impact of maintenance in the two trials (P of 
interaction = 0.04). It is not possible to determine if the different benefit in young and elderly 
patients is related to age only, or also to the different treatment administered (VT in elderly, R in 
young). Nevertheless, a higher rate of discontinuation was observed also among patients aged > 75 
years treated with lenalidomide maintenance (Palumbo et al. 2012).   
The analysis has other minor limitations. Data on cytogenetic profile were missing in about 30% of 
patients, and ISS data were lacking in 10% of patients.  
In both trials, maintenance randomization was performed at study entry, and not after induction and 
consolidation. To overcome this limitation, we performed a landmark analysis at 10 months 
(median duration of induction/consolidation) and we included only patients actually eligible for 
maintenance.  
Of note, a higher proportion of patients aged ≤ 65 years obtained less than a CR after 
induction/consolidation therapy, if compared with elderly patients. Younger patients were mostly 
enrolled in the RV-MM-PI-209 trial: they received lenalidomide and dexamethasone (Rd) induction 
and half of them were treated with melphalan-prednisone-lenalidomide consolidation, which is now 
considered a suboptimal induction-consolidation approach (Palumbo et al. 2014b).  
PFS2 was not a prespecified objective in the original study protocols. When the date of progression 
after second-line therapy was not available, the start date of third-line therapy was used to estimate 
PFS2. Second line therapies can impact on PFS2 and OS, yet they were not prespecified in both 
study protocols and they were mostly left to the investigators’ discretion. 
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Maintenance therapy plays an important role in maintaining response and consequently in 
improving survival in MM. CR, as was defined by IMWG criteria applied at the time of the two 
trials, is certainly a suboptimal marker of outcome. The IMWG has recently revised response 
criteria and added new definitions of CR besides the standard categories, according to the new 
sensitive techniques available to detect MRD (Paiva et al. 2008, 2011, 2012; Kumar et al. 2016). 
Unfortunately, no MRD data were available at time of analysis, thus it was not possible to evaluate 
how many CR-MRD positive patients improved to MRD negative status with maintenance, or to 
define the impact of maintenance in terms of long-term survival in these patients.  
In conclusion, maintenance therapy improved PFS1, PFS2 and OS in MM patients independently of 
response achieved after induction/consolidation therapy (CR or VGPR/PR), with the highest 
survival rates with prolonged treatment in patients achieving CR. This could of be partly related to a 
suboptimal definition of CR if compared with the new response criteria including MRD, even if 
similar features have been recently seen also in MRD negative patients. However, CR is still the 
easiest and most widespread method of response evaluation and our data suggest that maintenance 
therapy should be administered regardless of patient response to maximize outcome. Further studies 
on the use of MRD will clarify this issue; if the achievement of MRD negativity will imply cure of 
the disease, maintenance therapy could probably be stopped. Nevertheless, if MRD negativity will 
be associated with a higher chemo-sensitivity and a subsequent higher burden reduction but not 
really with cure, maintenance therapy will then remain a good strategy to keep the disease under 
control. 
Prospective randomized trials evaluating a response-adapted approach – possibly including MRD 
negativity and sustained MRD negativity – are needed to clarify the role of prolonged treatment 
according to response. 
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Supplementary material: please, see the Supplementary Appendix file. 
The two source studies are registered at ClinicalTrials.gov, numbers NCT01063179 and 
NCT00551928. 
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Titles and legends to figures 
 
Figure 1 - Progression-free survival 1 according to maintenance/ no maintenance in CR patients: 
(A) analysis in all patients; (B) subgroup analysis 
 
Figure 2 - Progression-free survival 2 according to maintenance/ no maintenance in CR patients:  
(A) analysis in all patients; (B) subgroup analysis 
 
Figure 3 - Overall survival according to maintenance/ no maintenance in CR patients: 
(A) analysis in all patients; (B) subgroup analysis 
 
Figure 4 - Survival curves according to best response achieved and maintenance/no maintenance 
therapy: (A) Progression free survival 1; (B) Progression free survival 2; (C) Overall survival 
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Figures 
 
Figure 1. Progression-free survival 1 according to maintenance/ no maintenance in CR patients  
 
Panel A – Analysis in all patients 
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Panel B – Subgroup analysis 
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Figure 2. Progression-free survival 2 according to maintenance/ no maintenance in CR patients 
  
Panel A – Analysis in all patients 
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Panel B – Subgroup analysis 
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Figure 3. Overall survival according to maintenance/ no maintenance in CR patients 
 
Panel A – Analysis in all patients 
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Panel B – Subgroup analysis 
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Figure 4. Survival curves according to best response achieved and maintenance/no maintenance 
therapy 
 
Panel A – Progression free survival 1 
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Panel B – Progression free survival 2 
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Panel C – Overall survival 
 
 
 
